By Marie Rosenthal, MS
The FDA approved dolutegravir-lamivudine (DTG/3TC; Dovato, ViiV Healthcare) as a complete regimen to treat HIV-1 infection in adults with no antiretroviral treatment (ART) history and with no known or suspected substitutions associated with resistance to the individual components of the combination.
Dovato combines the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay, 50 mg) with the nucleoside analogue reverse transcriptase inhibitor (NRTI)